These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 3623742)

  • 1. Elimination of 16-acetyl-gitoxin in patients suffering from impaired liver function.
    Haustein KO; Sensing H; Wesser M
    Int J Clin Pharmacol Ther Toxicol; 1987 Jul; 25(7):379-81. PubMed ID: 3623742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the pharmacokinetics of pengitoxin and its cardioactive derivative 16-acetyl-gitoxin.
    Haustein KO; Alken RG; Lach HJ; Becker U; Rietbrock N
    Eur J Clin Pharmacol; 1983; 25(3):369-73. PubMed ID: 6628525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of pengitoxin and its therapeutic efficacy in congestive heart failure.
    Haustein KO; Wesser M
    Int J Clin Pharmacol Ther Toxicol; 1988 Jan; 26(1):8-15. PubMed ID: 3403092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the pharmacokinetics of 16-acetyl-gitoxin and its bioavailability from pengitoxin-containing tablet formulations.
    Haustein KO
    J Pharmacokinet Biopharm; 1986 Aug; 14(4):357-64. PubMed ID: 3772737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetics of beta-methyldigoxin and beta-acetyldigoxin in patients with cirrhosis of the liver (author's transl)].
    Rameis H; Bonelli J; Waginger H; Hruby K
    Wien Klin Wochenschr; 1981 Oct; 93(18):572-6. PubMed ID: 7303703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in metildigoxin pharmacokinetics in cirrhosis of the liver: a comparison with beta-acetyldigoxin.
    Rameis H; Woodcock B; Bonelli J; Waginger H
    Int J Clin Pharmacol Ther Toxicol; 1984 Mar; 22(3):145-51. PubMed ID: 6715083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac effects of 16-acetyl-gitoxin, the active glycoside after penta-acetyl-gitoxin administration.
    Haustein KO; Hauptmann J; Nowak G
    Acta Biol Med Ger; 1978; 37(11-12):1713-20. PubMed ID: 754425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation into the species-specific deacylation of penta-acetyl-gitoxin.
    Haustein KO; Pachaly C; Megges R; Franke P
    Eur J Clin Pharmacol; 1978 Dec; 14(6):425-30. PubMed ID: 738349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the plasma protein binding of 16-acetyl-gitoxin.
    Hüller G; Haustein KO; Murawski D
    Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):200-2. PubMed ID: 7251233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct radioimmunoassay for the determination of 16-acetyl-gitoxin in serum.
    Weiler EW; Lach HJ
    Clin Chim Acta; 1980 Jul; 104(3):337-43. PubMed ID: 7389142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent shortening of systolic time intervals after intake of pengitoxin.
    Haustein KO; Hentschel H
    Int J Clin Pharmacol Res; 1987; 7(1):19-25. PubMed ID: 3583485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uptake and liberation of [3H]16-acetyl-gitoxin in the isolated guinea pig atrium.
    Glusa E; Haustein KO
    Biomed Biochim Acta; 1987; 46(1):119-23. PubMed ID: 3579884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological reevaluation of gitoxin in man.
    Lesne M
    Int J Clin Pharmacol Biopharm; 1978 Oct; 16(10):456-9. PubMed ID: 700907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preliminary study of the bioavailability of digoxin, desacetyllanatoside C and of acetyl-digoxin in oral administration].
    Rasetti G; Trimarco B; Vitale D; Pastore N; Ricciardelli B; Violini R; Consalvo G; Rengo F
    Boll Soc Ital Cardiol; 1977; 22(7):1064-72. PubMed ID: 618242
    [No Abstract]   [Full Text] [Related]  

  • 15. Biotransformation and uric acid lowering effect of benzbromarone in patients with liver cirrhosis - evidence for active benzbromarone metabolites?
    Walter-Sack I; de Vries JX; von Bubnoff A; Pfleilschifter V; Raedsch R
    Eur J Med Res; 1995 Oct; 1(1):16-20. PubMed ID: 9392688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Plasma levels of gitoxin (by RIA and rubidium-86 uptake) and systolic time after treatment with a single dose of gitoformate].
    Dei Cas L; Affatato A; Buia E; Casciarri G; Faggiano P; Giunti G; Metra M; Pelagatti T; Quinzanini M
    Cardiologia; 1984; 29(5-6):291-300. PubMed ID: 6542412
    [No Abstract]   [Full Text] [Related]  

  • 17. Impaired elimination of meperidine in patients with liver disease.
    McHorse TS; Klotz U; Wilkinson G; Schenker S
    Trans Assoc Am Physicians; 1974; 87():281-7. PubMed ID: 4456737
    [No Abstract]   [Full Text] [Related]  

  • 18. Half-life time or clearance of indocyanine green in patients with liver disease.
    Gilmore IT; Marigold JH; Thompson RP
    Hepatogastroenterology; 1982 Apr; 29(2):55-7. PubMed ID: 7084884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extraordinary efficacy of 16 alpha-gitoxin, an ultra-short acting semi-synthetic digitalis glycoside.
    Haustein KO; Bauer R
    Int J Clin Pharmacol Ther; 1994 Jun; 32(6):299-304. PubMed ID: 7921531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative study of oral absorption of beta-acetyldigoxin and digoxin].
    Di Michele D; Albanesi I; Moschetta D; D'Alesio R; Luchetti L
    Clin Ter; 1988 May; 125(3):179-83. PubMed ID: 2973938
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.